A double requalification allows DR SULAIMAN AL-HABIB to improve to Slightly Positive
DR SULAIMAN AL-HABIB (SA), a company active in the Health Care Providers industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 3 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date March 11, 2022, the closing price was SAR 179.60 and its potential was estimated at SAR 190.01.Dr Sulaiman Al-Habib Medical Services Group Co. Dr. Sulaiman Al-Habib Medical Services Group Company is a Saudi Arabia-based company engaged in health care sector. The Company operates through it's subsidiaries in three segments: Hospitals, Pharmacies and Other. The Hospital segment is engaged in setting up, managing and operating hospitals, medical facilities, pharmacies and medical diagnostic and radiological laboratories. The Pharmacies segment operates Al Habib Pharmacies, Middle East Pharmacies Company and Afia Pharmacies Company. The Other segments include management and operations services for third party, home healthcare service, intensive care units, ambulatory transportation, facility maintenance services information technology and systems services, cloud solutions, among others. The Company also provides import and export, wholesale and retail sale of medicines, medical and herbal products, cosmetics, medical devices and equipment.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.